Xefocam, powder for solution for injection 8mg x 5 vials — Made in Austria — Free Delivery

Short-term symptomatic treatment of acute mild to moderate pain in adults.

- hypersensitivity to lornoxicam or to the components of the preparation

- thrombocytopenia

- hypersensitivity (symptoms similar to those of asthma, rhinitis, angioedema or urticaria) to other NSAIDs, including acetylsalicylic acid

- severe form of heart failure

- gastrointestinal bleeding, cerebrovascular or other bleeding

- history of gastrointestinal bleeding or perforation associated with previous NSAID therapy

- active recurrent gastric ulcer/bleeding or history of recurrent gastric ulcer/bleeding (two or more separate episodes of advanced ulcer or bleeding)

- severe liver failure

- severe form of renal failure (serum creatinine > 700 µmol/l);

- III trimester of pregnancy (see section "Use during pregnancy or lactation").

active ingredient: lornoxicam;

1 bottle contains 8 mg of lornoxicam;

excipients: mannitol (E 421), trometamol, sodium edetate.

This dosage form of the preparation is intended to initiate therapy and when it is necessary to quickly achieve an analgesic effect or when the use of oral preparations  is not possible. In general, treatment should include only one injection to start therapy. For all patients, the appropriate dosing regimen should be based on the individual response to treatment. Side effects can be minimized if the minimum effective dose of the preparation is used for a short period of time, which is necessary to control symptoms (see section "Peculiarities of use").

This dosage form is intended for intravenous and intramuscular administration.

The recommended dose is 8 mg intravenously or intramuscularly. The daily dose should not exceed 16 mg. Some patients require an additional dose of 8 mg in the first 24 hours.

The duration of the introduction of the solution should be at least 15 seconds, intramuscular - at least 5 seconds.

Children.

The preparation is not recommended for use in children under 18 years of age due to insufficient clinical data on the efficacy and safety of the preparation.